Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025, at 9:00 am ET.
https://mma.prnewswire.com/media/2646316/Edgewise_Therapeutics_Logo.jpg
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations pageand will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to:www.edgewisetx.comor follow us onLinkedIn,X,FacebookandInstagram.
https://c212.net/c/img/favicon.png?sn=LA85579&sd=2025-05-14
View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference-on-may-20-2025-302452775.html
SOURCE Edgewise Therapeutics
https://rt.newswire.ca/rt.gif?NewsItemId=LA85579&Transmission_Id=202505140800PR_NEWS_USPR_____LA85579&DateId=20250514